PIK3CA mutations also appear to have a significant interest in the prediction of response to targeted therapies, as many drugs specifically targeting PI3K or other effectors of the PI3K/AKT pathway are intended to be administered only to patients with tumor bearing a mutation of PIK3CA, which makes the somatic mutations detection more and more important [62]. Here, AKT1 is linked to neoplasm.